NZ242271A - Medicaments containing a vitamin d compound stabilised by a basic substance - Google Patents

Medicaments containing a vitamin d compound stabilised by a basic substance

Info

Publication number
NZ242271A
NZ242271A NZ242271A NZ24227192A NZ242271A NZ 242271 A NZ242271 A NZ 242271A NZ 242271 A NZ242271 A NZ 242271A NZ 24227192 A NZ24227192 A NZ 24227192A NZ 242271 A NZ242271 A NZ 242271A
Authority
NZ
New Zealand
Prior art keywords
active compound
vitamin
heat
composition
pharmaceutical preparation
Prior art date
Application number
NZ242271A
Other languages
English (en)
Inventor
Itoh Hiroki
Tabata Tetsuro
Kikuta Jun-Ichi
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NZ242271A publication Critical patent/NZ242271A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ242271A 1991-04-09 1992-04-08 Medicaments containing a vitamin d compound stabilised by a basic substance NZ242271A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7621091 1991-04-09
JP1909992 1992-02-04

Publications (1)

Publication Number Publication Date
NZ242271A true NZ242271A (en) 1993-10-26

Family

ID=26355908

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ242271A NZ242271A (en) 1991-04-09 1992-04-08 Medicaments containing a vitamin d compound stabilised by a basic substance

Country Status (14)

Country Link
US (1) US5487900A (OSRAM)
EP (1) EP0508756B1 (OSRAM)
JP (1) JPH05279260A (OSRAM)
KR (1) KR100231633B1 (OSRAM)
AT (1) ATE144424T1 (OSRAM)
AU (1) AU649802B2 (OSRAM)
CA (1) CA2065603C (OSRAM)
DE (1) DE69214704T2 (OSRAM)
DK (1) DK0508756T3 (OSRAM)
ES (1) ES2094290T3 (OSRAM)
GR (1) GR3021892T3 (OSRAM)
IE (1) IE75709B1 (OSRAM)
NZ (1) NZ242271A (OSRAM)
TW (1) TW212761B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701264A1 (de) * 1997-01-16 1998-07-23 Kief Lizenz Verwertungsgesells Heilmittel, enthaltend Betasitosterin und/oder Phytosterol/Betasitosteringemische
AU2001278956B2 (en) * 2000-07-18 2007-04-05 Genzyme Corporation Stabilized 1alpha-hydroxy vitamin d
CA2425367A1 (en) * 2000-08-30 2003-04-07 Chugai Seiyaku Kabushiki Kaisha Oct formulations
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンd化合物を含む薬学的組成物
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2924200C (en) * 2005-10-12 2017-09-05 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
WO2007092755A2 (en) 2006-02-03 2007-08-16 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
EP3335712B1 (en) 2007-04-25 2025-09-10 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP2148661B1 (en) 2007-04-25 2012-12-12 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンd治療法
JP7085105B2 (ja) * 2016-11-10 2022-06-16 日産化学株式会社 ビタミンd3誘導体の製剤
PE20211489A1 (es) 2018-08-31 2021-08-11 Opko Ireland Global Holdings Ltd Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンd↓3類組成物
JPS6217A (ja) * 1985-02-14 1987-01-06 Chugai Pharmaceut Co Ltd 安定な活性型ビタミンd3類製剤
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンd▲下3▼類固型製剤
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンd↓3類含有組成物

Also Published As

Publication number Publication date
US5487900A (en) 1996-01-30
GR3021892T3 (en) 1997-03-31
KR920019346A (ko) 1992-11-19
ATE144424T1 (de) 1996-11-15
EP0508756B1 (en) 1996-10-23
CA2065603A1 (en) 1992-10-10
IE921126A1 (en) 1992-10-21
JPH05279260A (ja) 1993-10-26
EP0508756A1 (en) 1992-10-14
DE69214704T2 (de) 1997-04-17
KR100231633B1 (ko) 1999-11-15
DE69214704D1 (de) 1996-11-28
ES2094290T3 (es) 1997-01-16
DK0508756T3 (da) 1997-03-24
CA2065603C (en) 2007-04-03
AU1480492A (en) 1992-10-15
TW212761B (OSRAM) 1993-09-11
IE75709B1 (en) 1997-09-10
AU649802B2 (en) 1994-06-02

Similar Documents

Publication Publication Date Title
EP0508756B1 (en) Stabilized vitamin D preparation
JP2525478B2 (ja) 安定性の改良された活性型ビタミンd▲下3▼類固型製剤
US4404183A (en) Sustained release pharmaceutical composition of solid medical material
US5328903A (en) Composition for solid pharmaceutical preparations containing vitamin D3 derivative
EP1446010B1 (en) Stabilized azithromycin compositions
US20080248101A1 (en) Pharmaceutical composition containing fenofibrate and method for the preparation thereof
EP0567201A2 (en) Vehicles for oral administration of a specific pharmaceutically active acid labile substance
US4620974A (en) Pharmaceutical composition containing a liquid lubricant
JP2001261577A (ja) 医薬用製剤の酸化分解の抑制
EP4410793A1 (en) Solid composition of glp-1 receptor agonist
US4832952A (en) Pharmaceutical composition containing a liquid lubricant
WO1992009271A1 (en) Composition for solid pharmaceutical preparations containing active vitamins d3 and process for preparation thereof
US20080038332A1 (en) Stable pharmaceutical formulation comprising atorvastatin calcium
EP3184103A1 (en) Pharmaceutical composition comprising atorvastatin or a salt thereof
JP3037393B2 (ja) 経口投与用固形薬剤の製造方法
CA3190856A1 (en) Solid dosage forms of palbociclib
JP2914690B2 (ja) 安定なビタミンd▲下3▼類含有製剤
JP2963718B2 (ja) ビタミンd▲下3▼類含有製剤
JPH0474123A (ja) 安定な活性型ビタミンd↓3類製剤
JPH0640921A (ja) 活性型ビタミンd3 類組成物
JP3572620B2 (ja) ビタミンd3含有固形製剤組成物
US20100178338A1 (en) Stabilized pharmaceutical compositions comprising atorvastatin
EP4427742A1 (en) Pharmaceutical compositions comprising dapagliflozin and metformin
KR100514590B1 (ko) 프라바스타틴나트륨 및 안정화제로서의 코폴리비돈을함유하는 약제 조성물
JPH05246854A (ja) ビタミンd3含有固形製剤組成物

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired